News

Oracle Forecasts $100 Billion in Revenue by Fiscal 2029

Oracle Forecasts $100 Billion in Revenue by Fiscal 2029

Oracle Projects Major Revenue Growth by Fiscal 2029

There’s some good news for Oracle (NYSE: ORCL) as its shares jumped over 6% in premarket trading, thanks to an exciting announcement regarding its future revenue plans. The tech giant aims to surpass $100 billion in sales by fiscal 2029, driven primarily by the growing demand for cloud services fueled by artificial intelligence.

The Role of Cloud Services in Business Operations

Today's businesses depend heavily on cloud services, with significant players like Oracle, Microsoft (NASDAQ: MSFT), and Amazon providing the crucial infrastructure needed for daily operations and enhancing AI capabilities. As more organizations embrace digital transformation, the demand for comprehensive cloud solutions has soared, unlocking major revenue opportunities for these technology companies.

Analysts React to Oracle's Promising Forecast

Analysts at brokerage Piper Sandler commented that while Oracle's expectations might seem ambitious, they nonetheless reflect a growing sense of optimism from a management team known for its resilience. This analysis comes shortly after Oracle announced its surprising revenue forecast for fiscal 2029, which has piqued the interest of both investors and market analysts.

Strong Clientele and Continued Revenue Growth

Oracle serves a diverse range of clients, including major names like AT&T (NYSE: T), Lyft (NASDAQ: LYFT), and Cognizant (NASDAQ: CTSH). This broad clientele positions Oracle favorably to take advantage of its anticipated revenue growth. Moreover, the company recently raised its revenue forecast for fiscal 2026 to $66 billion, a slight increase from the previous estimate of $65 billion, indicating solid financial momentum.

Performance in the Cloud Market

On a recent Monday, Oracle made headlines by announcing its outstanding first-quarter revenue of $13.31 billion—well above analysts’ expectations. During an annual briefing focused on financial analysts, the company shared its projections for fiscal 2029 and updated its fiscal 2026 revenue outlook, reinforcing its strong position in the industry.

Comparative Performance Against Rivals

This year, Oracle's stock has surged by over 50%, outpacing larger competitors in the cloud computing landscape. In contrast, Microsoft and Amazon's stocks have increased by approximately 14% and 23%, respectively. This impressive performance highlights Oracle's growing status in the market.

Market Position and Price-to-Earnings Ratio

Looking to the future, brokerage Bernstein noted that Oracle is in a surprisingly strong position to capture a more substantial share of the cloud services market. With a forward price-to-earnings ratio of 24.65, Oracle presents a more attractive valuation than Microsoft (31.52) and Amazon (33.73). After Oracle’s positive fiscal forecasts, at least six brokerage firms have increased their target prices, reflecting strong confidence in the company’s growth path.

Frequently Asked Questions

What is Oracle's projected revenue by fiscal 2029?

Oracle plans to exceed $100 billion in revenue by fiscal 2029, primarily driven by the increasing demand for AI and cloud services.

Which companies are Oracle's main competitors in cloud services?

Oracle competes mainly with Microsoft and Amazon, both of which provide comparable cloud services to businesses around the globe.

How did Oracle perform in the first quarter?

In the first quarter, Oracle reported $13.31 billion in revenue, beating the expectations of analysts.

What recent changes did Oracle make to its revenue forecasts?

Oracle has updated its revenue forecast for fiscal 2026 to $66 billion, up from the previous prediction of $65 billion, indicating ongoing financial growth.

How has Oracle's stock performed this year?

So far this year, Oracle's stock has increased over 50%, significantly outperforming its larger competitors in the cloud computing industry.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Harbour BioMed Joins Stock Connect, Boosts Investor Access

Updated Category News Views 3

The Big Leap: Harbour BioMed Joins Stock Connect Well, if this ain't something to get excited about—Harbour BioMed just snagged a spot on the Stock Connect roster. This step isn't just ceremonial. We're talking about real access for mainland Chinese investors to dive directly into the shares of Harbour BioMed (HKEX: 02142.HK) through the Shanghai-Hong Kong and...

Continue Reading
Park Systems Expands in the Pacific Northwest

Updated Category News Views 3

Strategic Move into Hillsboro Sparks Industry Buzz Park Systems, already a heavyweight in the nanometrology arena, just made a bold play with the opening of its latest regional office. Nestled in the tech-centric town of Hillsboro, Oregon, this hub is set to redefine how they handle technical support and customer management across the Pacific Northwest. It's like they're...

Continue Reading
DUVA ONE Sleep Earbuds: Real-Time Innovation Debuts

Updated Category News Views 3

While You Dream, DUVA ONE Works Here's the scoop: DUVA just took sleep tech to another level with their DUVA ONE earbuds launched at Berlin's IFA 2026. These aren't just any earbuds; they're engineered to actually do something while you're sleeping. DUVA ONE senses what’s happening during your snooze session and adjusts right on the fly. The Night Patrol: In-Ear and...

Continue Reading
Roborock Fuels Market Surge with 27.6% Revenue Boost

Updated Category News Views 2

Roborock's Rocket-Like Ascent in Global Markets Call me impressed, but Roborock is really hitting its stride. The company's been on a tear, pulling in RMB 10.084 billion during the first half of 2026—a remarkable 27.6% bump from last year. Not just content with the revenue surge, they also saw net profits jump 45.6%, making it pretty clear that they're not just playing...

Continue Reading
York Space Systems Faces Class Action Over Misleading IPO

Updated Category News Views 2

York Space Systems Under the Legal Spotlight Ever get that feeling when something just doesn’t sit right? Like a burr under the saddle, York Space Systems is now grappling with a class action lawsuit that's throwing a heap of shade on its recent moves. What’s at play? Bronstein, Gewirtz & Grossman, LLC, a law firm that seems to have a nose for corporate messes, has...

Continue Reading
Summit Tackles BRI Infrastructure's Role in Global SDGs

Updated Category News Views 3

A Bold Gathering with Lofty Goals Ever watch a room of world leaders debate the finer nuances of sustainable infrastructure? That's something Singapore pulled off on September 6, 2026, with the Second Global Business Summit on Belt and Road Infrastructure Investment. These aren't just any ordinary suits sitting around in a conference room. We're talking about a dynamic...

Continue Reading
Clover's RSV Combo Vaccine Shows Promise in Trials

Updated Category News Views 3

In the biotech world, there's always a race. Clover Biopharmaceuticals is making strides with their RSV+hMPV vaccine candidate, especially for the elderly. Imagine those big leaps in development—all boosted by recent results from a Phase 2 trial down under in Australia. Key Findings of the Trial Immunogenicity Insights They're not messing around with these findings. The...

Continue Reading
Hims & Hers Faces Class Action: Investors Beware

Updated Category News Views 2

Allegations and Legal Pressure There's trouble brewing in the land of health and wellness apps, with Hims & Hers Health, Inc. (NYSE:HIMS) taking center stage. Slap on your glasses, folks, because this one's a doozy. A class-action lawsuit has exploded against the company and some of its officers—allegations flying as they focus on serious accusations of misleading...

Continue Reading
Bad Bunny Super Bowl Halftime Show Sweeps 7 Emmy Wins

Updated Category News Views 6

An Unprecedented Performance: A Halftime Show for the Ages Hold onto your hats, folks—Bad Bunny and his Super Bowl LX Halftime Show have taken home a jaw-dropping seven Emmys at the 78th Emmy Awards. This is uncharted territory for any Super Bowl Halftime Show. Never before has a halftime spectacle swept the Emmys like this. We’re talking about categories such as...

Continue Reading
XiamenAir Takes Off with Fujian-London Link

Updated Category News Views 2

A New Dawn for Fujian Travelers Here's a nugget to chew on: XiamenAir's first-ever direct flight from Xiamen to London had its moment in the spotlight. This isn't just another intercontinental flyby—it's a game-changer for folks in Fujian looking to hop across the pond without the layover hassle. With Flight MF821 touching down in Heathrow early on September 6th, this...

Continue Reading

Top 5 Most Recently Viewed Articles

Big Screen Entertainment Group Unveils Big Screen Capital Fund

Updated Category News Views 138

Introducing Big Screen Capital Big Screen Entertainment Group (OTC:BSEG) has just announced the launch of its new funding subsidiary, Big Screen Capital. This exciting development is set to finance a range of creative projects, including the establishment of the Big Film Fund, as well as two upcoming films and advancements in medical technology. With this strategic move,...

Continue Reading
Air Products Faces Integrity Challenges: A Call for Change

Updated Category News Views 129

Understanding the Recent Calls for Change at Air Products Mantle Ridge has taken a bold step by issuing a shareholder letter that highlights critical concerns regarding Air Products and Chemicals, Inc. The organization, which owns approximately $1.3 billion in shares of Air Products, has pointed out various omissions and misleading statements from the company’s...

Continue Reading
Navigating Key Market Shifts in H2 2026: A Crucial Period

Updated Category News Views 5

The Intensity of Mid-2026: Traders Brace for Impact Traders are steeling themselves for July's rollercoaster of central bank decisions. This isn't just another season; it's a potential market earthquake. When you've got the European Central Bank, Bank of England, and Federal Reserve all signaling rate announcements within days, it's time to pay more than a little...

Continue Reading
Summary of Recent Extraordinary General Meeting Outcomes

Updated Category News Views 158

Results of Extraordinary General Meeting Announcement German High Street Properties A/S is pleased to present the results from the extraordinary general meeting that took place. This meeting marks a significant moment for the company and its shareholders as they come together to discuss essential matters affecting the company's future. Date and Purpose of the Meeting The...

Continue Reading
Tectonic Therapeutics Advances TX45 for Heart Failure Treatment

Updated Category News Views 166

Tectonic Therapeutics Advances TX45 for Heart Health Tectonic Therapeutic, Inc. (NASDAQ: TECX), an innovative biotechnology company, has announced promising outcomes from its Phase 1a trials, which could lead to significant progress in treating Group 2 Pulmonary Hypertension in patients experiencing Heart Failure with Preserved Ejection Fraction (PH-HFpEF). The results...

Continue Reading